

STATE OF WISCONSIN
CONTROLLED SUBSTANCES BOARD

IN THE MATTER OF RULE-MAKING : AFFIRMATIVE ACTION
PROCEEDINGS BEFORE THE : ORDER OF THE
CONTROLLED SUBSTANCES BOARD : CONTROLLED SUBSTANCES BOARD

FINDINGS

1. On April 7, 2022, the Department of Justice, Drug Enforcement Administration published its interim final rule in the Federal Register listing Daridorexant into schedule IV of the federal Controlled Substances Act. The scheduling action is effective April 7, 2022.
2. The Controlled Substances Board did not receive an objection to similarly listing Daridorexant as a schedule IV under ch. 961, Stats. within 30 days of the date of publication in the federal register of the interim final order listing Daridorexant as a schedule IV controlled substance.
3. The Controlled Substances Board will promulgate a final rule, without making the determinations or findings required by ss. 961.11(1), (1m), (1r) and (2) or s. 961.19 and omitting the notice of proposed rulemaking, listing Daridorexant as a schedule IV controlled substance.

ORDER

Pursuant to s. 961.11(4), Stats., the Controlled Substances Board by affirmative action similarly treats Daridorexant under chapter 961, Stats. by creating the following:

CSB 2.93 Addition of Daridorexant to schedule IV. Section 961.20 (2) (cpm), Stats., is created to read:

961.20 (2) (cpm) Daridorexant.

This order shall become effective upon publication in the Administrative Register. The order expires upon promulgation of a final rule.

Dated 07/20/22

Douglas Englebort

Doug Englebort, Chair
Controlled Substances Board